EFG Asset Management North America Corp. Grows Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

EFG Asset Management North America Corp. increased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 59.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,160 shares of the company's stock after buying an additional 27,192 shares during the quarter. EFG Asset Management North America Corp. owned 0.12% of Vera Therapeutics worth $3,092,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of VERA. Prudential Financial Inc. boosted its holdings in Vera Therapeutics by 33.6% during the 4th quarter. Prudential Financial Inc. now owns 83,077 shares of the company's stock worth $3,513,000 after acquiring an additional 20,880 shares during the last quarter. Corebridge Financial Inc. boosted its holdings in Vera Therapeutics by 5.8% during the fourth quarter. Corebridge Financial Inc. now owns 22,047 shares of the company's stock worth $932,000 after purchasing an additional 1,210 shares during the last quarter. Vanguard Group Inc. grew its position in Vera Therapeutics by 14.3% in the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock worth $124,737,000 after purchasing an additional 369,387 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Vera Therapeutics in the 4th quarter valued at about $431,000. Finally, American Century Companies Inc. increased its stake in Vera Therapeutics by 11.0% in the 4th quarter. American Century Companies Inc. now owns 428,940 shares of the company's stock valued at $18,140,000 after buying an additional 42,526 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Marshall Fordyce sold 17,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the completion of the transaction, the chief executive officer now directly owns 143,603 shares in the company, valued at approximately $5,993,989.22. This trade represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.70% of the stock is owned by company insiders.

Vera Therapeutics Stock Performance

Vera Therapeutics stock traded up $0.11 during midday trading on Friday, reaching $26.63. The stock had a trading volume of 530,032 shares, compared to its average volume of 760,878. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.70 billion, a PE ratio of -10.20 and a beta of 1.17. Vera Therapeutics, Inc. has a 12 month low of $25.55 and a 12 month high of $51.61. The firm's 50-day moving average price is $30.93 and its 200 day moving average price is $38.87.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.11. As a group, research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. cut their target price on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. Guggenheim upped their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Wolfe Research began coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 target price for the company. Finally, The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.